Summary of Key Information:

Reporting Period: Not Applicable (Corporate Action)

Nature of Filing / Announcement: Outcome of Board Meeting - Acquisition Announcement

Date of Board Meeting / Approval: September 24, 2026

Meeting Duration: Commenced at 04:40 P.M. (IST) and concluded at 05:11 P.M. (IST)

Corporate Actions:

Acquisition Details:

  • Acquisition of 70% stake in SN Genelab Private Limited (SN Gene) from existing shareholders
  • Post-acquisition, SN Gene will become a subsidiary of Dr. Lal PathLabs Limited
  • Consideration: Cash consideration of up to INR 168 Crores plus certain performance-linked earn out capped at INR 31.5 Crores for 70% stake
  • Expected completion date: November 30, 2026

Target Company Information:

  • Name: SN Genelab Private Limited
  • Industry: Diagnostics - Genomics
  • Date of Incorporation: December 16, 2013 (State of Gujarat)
  • Business: Providing Diagnostics - Genomics services

Financial Performance of SN Gene:

  • FY 2026 Turnover: ₹57.96 Crores
  • FY 2025 Turnover: ₹53.36 Crores
  • FY 2024 Turnover: ₹43.27 Crores

Strategic Rationale:

To strengthen the Company's expertise in genomics and broaden its portfolio of advanced diagnostic services.

Regulatory Aspects:

  • Not a related party transaction
  • No governmental or regulatory approvals required for the acquisition
  • Transaction conducted at arm's length basis

Other Significant Information:

Company Representative: Vinay Gujral, Company Secretary & Compliance Officer

#DrLalPathLabs #Acquisition #M&A #GenomicsDiagnostics #CorporateAction